Although patients with MLL-rearranged leukemia usually show a poor prognosis and are sometimes resistant to therapy [3], [4], the development of efficient therapies targeting the MLL-fusion genes has been slow, in part because much is still unknown about the cellular and molecular mechanisms underlying this disease. The gene discussed is KMT2A; the disease is leukemia.